Virax Biolabs Group Ltd (VRAX)
1.94
+0.01
(+0.52%)
USD |
NASDAQ |
Sep 27, 16:00
1.94
0.00 (0.00%)
After-Hours: 20:00
Virax Biolabs Group Enterprise Value: 4.606M for Sept. 27, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 27, 2024 | 4.606M |
| September 26, 2024 | 4.563M |
| September 25, 2024 | 4.823M |
| September 24, 2024 | 4.563M |
| September 23, 2024 | 5.865M |
| September 20, 2024 | 6.777M |
| September 19, 2024 | 7.168M |
| September 18, 2024 | 7.863M |
| September 17, 2024 | 8.644M |
| September 16, 2024 | 8.514M |
| September 13, 2024 | 7.429M |
| September 12, 2024 | 7.602M |
| September 11, 2024 | 9.165M |
| September 10, 2024 | 9.209M |
| September 09, 2024 | 10.03M |
| September 06, 2024 | 11.42M |
| September 05, 2024 | 13.68M |
| September 04, 2024 | 13.38M |
| September 03, 2024 | 15.94M |
| August 30, 2024 | 16.42M |
| August 29, 2024 | 18.15M |
| August 28, 2024 | 17.33M |
| August 27, 2024 | 17.42M |
| August 26, 2024 | 16.20M |
| August 23, 2024 | 19.85M |
| Date | Value |
|---|---|
| August 22, 2024 | 12.93M |
| August 21, 2024 | 16.87M |
| August 20, 2024 | 6.738M |
| August 19, 2024 | 9.438M |
| August 16, 2024 | 1.665M |
| August 15, 2024 | -0.2395M |
| August 14, 2024 | 0.6356M |
| August 13, 2024 | -0.4712M |
| August 12, 2024 | -0.3167M |
| August 09, 2024 | -0.8315M |
| August 08, 2024 | -1.037M |
| August 07, 2024 | -1.012M |
| August 06, 2024 | -1.166M |
| August 05, 2024 | -1.063M |
| August 02, 2024 | -0.9087M |
| August 01, 2024 | -0.9087M |
| July 31, 2024 | -0.6127M |
| July 30, 2024 | -0.5999M |
| July 29, 2024 | -0.5484M |
| July 26, 2024 | -0.291M |
| July 25, 2024 | -0.8058M |
| July 24, 2024 | -0.9859M |
| July 23, 2024 | -0.78M |
| July 22, 2024 | -0.9087M |
| July 19, 2024 | -0.8058M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-4.127M
Minimum
May 04 2023
236.34M
Maximum
Jul 28 2022
8.374M
Average
-0.8058M
Median
Jul 19 2024
Enterprise Value Benchmarks
| Adaptimmune Therapeutics PLC | 60.08M |
| Biodexa Pharmaceuticals PLC | -1.734M |
| Verona Pharma PLC | 2.051B |
| NuCana PLC | -9.217M |
| Autolus Therapeutics PLC | 259.98M |
Enterprise Value Related Metrics
| Earnings Yield | -921.9% |
| Normalized Earnings Yield | -917.49 |